DHX40
gene geneOn this page
Also known as ARG147PADFLJ22060
Summary
DHX40 (DEAH-box helicase 40, HGNC:18018) is a protein-coding gene on chromosome 17q23.1, encoding Probable ATP-dependent RNA helicase DHX40 (Q8IX18). Probable ATP-dependent RNA helicase.
This gene encodes a member of the DExH/D box family of ATP-dependent RNA helicases that have an essential role in RNA metabolism. Alternate splicing results in multiple transcript variants. A pseudogene of this gene is found on chromosome 17.
Source: NCBI Gene 79665 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 88 total
- Druggable target: yes
- MANE Select transcript:
NM_024612
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:18018 |
| Approved symbol | DHX40 |
| Name | DEAH-box helicase 40 |
| Location | 17q23.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ARG147, PAD, FLJ22060 |
| Ensembl gene | ENSG00000108406 |
| Ensembl biotype | protein_coding |
| OMIM | 607570 |
| Entrez | 79665 |
Gene structure
Transcript identifiers
Ensembl transcripts: 21 — 16 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay
ENST00000251241, ENST00000425628, ENST00000538926, ENST00000577549, ENST00000577596, ENST00000578204, ENST00000580030, ENST00000580218, ENST00000583439, ENST00000584385, ENST00000867586, ENST00000930678, ENST00000930679, ENST00000930680, ENST00000930681, ENST00000961852, ENST00000961853, ENST00000961854, ENST00000961855, ENST00000961856, ENST00000961857
RefSeq mRNA: 2 — MANE Select: NM_024612
NM_001166301, NM_024612
CCDS: CCDS11617, CCDS54150
Canonical transcript exons
ENST00000251241 — 18 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000739767 | 59577266 | 59577365 |
| ENSE00000739768 | 59579472 | 59579558 |
| ENSE00001046361 | 59575340 | 59575471 |
| ENSE00001112916 | 59605115 | 59605184 |
| ENSE00001137652 | 59579697 | 59579879 |
| ENSE00001137671 | 59574188 | 59574254 |
| ENSE00001137708 | 59565610 | 59565783 |
| ENSE00001207627 | 59599375 | 59599483 |
| ENSE00001207633 | 59587896 | 59588053 |
| ENSE00001207635 | 59586153 | 59586233 |
| ENSE00002269560 | 59607033 | 59608345 |
| ENSE00003475870 | 59602522 | 59602616 |
| ENSE00003510661 | 59605446 | 59605674 |
| ENSE00003515993 | 59570518 | 59570663 |
| ENSE00003537704 | 59573740 | 59573967 |
| ENSE00003593285 | 59598737 | 59598851 |
| ENSE00003648416 | 59566627 | 59566794 |
| ENSE00003669437 | 59573116 | 59573235 |
Expression profiles
Bgee: expression breadth ubiquitous, 290 present calls, max score 97.46.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 49.3232 / max 517.7107, expressed in 1818 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 161960 | 48.6783 | 1817 |
| 161961 | 0.6448 | 357 |
Top tissues by expression
292 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| ventricular zone | UBERON:0003053 | 97.46 | gold quality |
| bronchial epithelial cell | CL:0002328 | 95.53 | gold quality |
| ganglionic eminence | UBERON:0004023 | 94.80 | gold quality |
| epithelium of bronchus | UBERON:0002031 | 94.71 | gold quality |
| cartilage tissue | UBERON:0002418 | 94.68 | gold quality |
| bronchus | UBERON:0002185 | 94.52 | gold quality |
| calcaneal tendon | UBERON:0003701 | 94.31 | gold quality |
| embryo | UBERON:0000922 | 93.88 | gold quality |
| renal medulla | UBERON:0000362 | 93.79 | gold quality |
| tendon | UBERON:0000043 | 93.57 | gold quality |
| caput epididymis | UBERON:0004358 | 93.36 | gold quality |
| islet of Langerhans | UBERON:0000006 | 93.29 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 93.28 | gold quality |
| endometrium | UBERON:0001295 | 92.79 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 92.76 | gold quality |
| upper leg skin | UBERON:0004262 | 92.75 | gold quality |
| urethra | UBERON:0000057 | 92.68 | gold quality |
| skin of hip | UBERON:0001554 | 92.11 | gold quality |
| corpus epididymis | UBERON:0004359 | 91.90 | gold quality |
| sperm | CL:0000019 | 91.75 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 91.70 | gold quality |
| secondary oocyte | CL:0000655 | 91.52 | gold quality |
| synovial joint | UBERON:0002217 | 91.35 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 91.28 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 91.27 | gold quality |
| penis | UBERON:0000989 | 91.25 | gold quality |
| pericardium | UBERON:0002407 | 91.21 | gold quality |
| saphenous vein | UBERON:0007318 | 91.03 | gold quality |
| seminal vesicle | UBERON:0000998 | 91.00 | gold quality |
| epithelium of mammary gland | UBERON:0003244 | 90.99 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.44 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
71 targeting DHX40, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-574-5P | 100.00 | 66.01 | 989 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-4481 | 100.00 | 66.42 | 1669 |
| HSA-MIR-520D-5P | 99.98 | 73.34 | 4883 |
| HSA-MIR-524-5P | 99.98 | 73.43 | 4882 |
| HSA-MIR-19A-3P | 99.98 | 75.33 | 2762 |
| HSA-MIR-512-3P | 99.97 | 67.35 | 1049 |
| HSA-MIR-3658 | 99.96 | 73.87 | 4379 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-302E | 99.96 | 70.74 | 2669 |
| HSA-MIR-545-3P | 99.95 | 70.74 | 2783 |
| HSA-MIR-141-3P | 99.94 | 72.79 | 2421 |
| HSA-MIR-200A-3P | 99.94 | 72.68 | 2420 |
| HSA-MIR-627-3P | 99.90 | 71.42 | 3316 |
| HSA-MIR-4493 | 99.90 | 66.48 | 977 |
| HSA-MIR-6844 | 99.82 | 70.69 | 2423 |
| HSA-MIR-34B-5P | 99.78 | 67.56 | 1175 |
| HSA-MIR-449C-5P | 99.78 | 67.63 | 1168 |
| HSA-MIR-7856-5P | 99.75 | 69.99 | 2901 |
| HSA-MIR-6885-3P | 99.75 | 70.36 | 3187 |
| HSA-MIR-2682-5P | 99.73 | 67.38 | 1055 |
| HSA-MIR-4719 | 99.73 | 72.10 | 3329 |
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | dhx40 | ENSDARG00000041586 |
| mus_musculus | Dhx40 | ENSMUSG00000018425 |
| rattus_norvegicus | Dhx40 | ENSRNOG00000004549 |
Paralogs (18): DHX33 (ENSG00000005100), YTHDC2 (ENSG00000047188), DHX29 (ENSG00000067248), DHX8 (ENSG00000067596), DHX32 (ENSG00000089876), DHX35 (ENSG00000101452), DHX15 (ENSG00000109606), HELB (ENSG00000127311), DHX30 (ENSG00000132153), DHX34 (ENSG00000134815), DHX9 (ENSG00000135829), DHX38 (ENSG00000140829), DQX1 (ENSG00000144045), DHX37 (ENSG00000150990), TDRD9 (ENSG00000156414), DHX57 (ENSG00000163214), DHX36 (ENSG00000174953), DHX16 (ENSG00000204560)
Protein
Protein identifiers
Probable ATP-dependent RNA helicase DHX40 — Q8IX18 (reviewed: Q8IX18)
Alternative names: DEAH box protein 40, Protein PAD
All UniProt accessions (6): Q8IX18, F5H625, J3KS08, J3KSW6, J3KSX9, J3KTK0
UniProt curated annotations — full annotation on UniProt →
Function. Probable ATP-dependent RNA helicase.
Tissue specificity. Ubiquitously expressed.
Similarity. Belongs to the DEAD box helicase family. DEAH subfamily.
Isoforms (4)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q8IX18-1 | 1 | yes |
| Q8IX18-2 | 2 | |
| Q8IX18-3 | 3 | |
| Q8IX18-4 | 4 |
RefSeq proteins (2): NP_001159773, NP_078888* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001650 | Helicase_C-like | Domain |
| IPR002464 | DNA/RNA_helicase_DEAH_CS | Conserved_site |
| IPR007502 | Helicase-assoc_dom | Domain |
| IPR011545 | DEAD/DEAH_box_helicase_dom | Domain |
| IPR011709 | DEAD-box_helicase_OB_fold | Domain |
| IPR014001 | Helicase_ATP-bd | Domain |
| IPR027417 | P-loop_NTPase | Homologous_superfamily |
| IPR048333 | HA2_WH | Domain |
Pfam: PF00270, PF00271, PF04408, PF07717, PF21010
Catalyzed reactions (Rhea), 1 shown:
- ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)
UniProt features (17 total): splice variant 5, sequence conflict 4, domain 2, region of interest 2, chain 1, short sequence motif 1, compositionally biased region 1, binding site 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8IX18-F1 | 83.51 | 0.54 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (1): 76–83
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 204 (showing top):
GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GCM_GSPT1, SOX9_B1, MODULE_239, MARTINEZ_RB1_TARGETS_DN, ROZANOV_MMP14_TARGETS_UP, GOBP_RNA_SPLICING, TGANTCA_AP1_C, CCCNNNNNNAAGWT_UNKNOWN, AACTTT_UNKNOWN, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, CREB_Q3, YRTCANNRCGC_UNKNOWN, LEF1_Q6, GCM_NF2
GO Biological Process (1): mRNA splicing, via spliceosome (GO:0000398)
GO Molecular Function (10): RNA binding (GO:0003723), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), 3’-5’ RNA helicase activity (GO:0034458), nucleotide binding (GO:0000166), nucleic acid binding (GO:0003676), RNA helicase activity (GO:0003724), helicase activity (GO:0004386), protein binding (GO:0005515), hydrolase activity (GO:0016787)
GO Cellular Component (1): spliceosomal complex (GO:0005681)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| ATP-dependent activity | 2 |
| binding | 2 |
| RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 1 |
| mRNA processing | 1 |
| nucleic acid binding | 1 |
| adenyl ribonucleotide binding | 1 |
| purine ribonucleoside triphosphate binding | 1 |
| ribonucleoside triphosphate phosphatase activity | 1 |
| RNA helicase activity | 1 |
| nucleoside phosphate binding | 1 |
| heterocyclic compound binding | 1 |
| helicase activity | 1 |
| ATP-dependent activity, acting on RNA | 1 |
| catalytic activity, acting on RNA | 1 |
| nucleic acid conformation isomerase activity | 1 |
| catalytic activity, acting on a nucleic acid | 1 |
| catalytic activity | 1 |
| nuclear protein-containing complex | 1 |
| ribonucleoprotein complex | 1 |
Protein interactions and networks
STRING
2346 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| DHX40 | PON2 | Q15165 | 765 |
| DHX40 | PON1 | P27169 | 650 |
| DHX40 | TCEAL4 | Q96EI5 | 637 |
| DHX40 | YPEL2 | Q96QA6 | 629 |
| DHX40 | PON3 | Q15166 | 589 |
| DHX40 | NSRP1 | Q9H0G5 | 576 |
| DHX40 | FBXO38 | Q6PIJ6 | 529 |
| DHX40 | SLC35F4 | A4IF30 | 508 |
| DHX40 | RALGAPB | Q86X10 | 488 |
| DHX40 | CHCT1 | Q86WR6 | 474 |
| DHX40 | MAGED2 | Q9UNF1 | 456 |
| DHX40 | DDX24 | Q9GZR7 | 451 |
| DHX40 | FLVCR2 | Q9UPI3 | 449 |
| DHX40 | DDX49 | Q9Y6V7 | 444 |
| DHX40 | DDX55 | Q8NHQ9 | 438 |
IntAct
52 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| MED4 | MED19 | psi-mi:“MI:0914”(association) | 0.900 |
| USP7 | BCOR | psi-mi:“MI:0914”(association) | 0.660 |
| DNAJC7 | PLD2 | psi-mi:“MI:0914”(association) | 0.640 |
| DHX38 | DHX16 | psi-mi:“MI:0914”(association) | 0.630 |
| PSTPIP1 | DHX40 | psi-mi:“MI:0915”(physical association) | 0.560 |
| PSME1 | POLR3A | psi-mi:“MI:0914”(association) | 0.530 |
| IARS2 | GAK | psi-mi:“MI:0914”(association) | 0.530 |
| ZNRD2 | MYO9A | psi-mi:“MI:0914”(association) | 0.530 |
| DHX40 | TRIM27 | psi-mi:“MI:0914”(association) | 0.530 |
| ZNRD2 | CCDC85C | psi-mi:“MI:0914”(association) | 0.530 |
| USP7 | STIL | psi-mi:“MI:0914”(association) | 0.350 |
| JUN | psi-mi:“MI:0914”(association) | 0.350 | |
| APBB1 | SSPOP | psi-mi:“MI:0914”(association) | 0.350 |
| ESR1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| LRRK2 | psi-mi:“MI:0914”(association) | 0.350 | |
| G3BP1 | HAT1 | psi-mi:“MI:0914”(association) | 0.350 |
| M | psi-mi:“MI:0914”(association) | 0.350 | |
| CLK2 | PRPF4 | psi-mi:“MI:0914”(association) | 0.350 |
| TRIM52 | MEIOC | psi-mi:“MI:0914”(association) | 0.350 |
| PTGES3 | SBNO1 | psi-mi:“MI:0914”(association) | 0.350 |
| ATXN7L1 | USP27X | psi-mi:“MI:0914”(association) | 0.350 |
| CAPN12 | KIF2A | psi-mi:“MI:0914”(association) | 0.350 |
| AKR7L | KIF2A | psi-mi:“MI:0914”(association) | 0.350 |
| RNF7 | SOCS2 | psi-mi:“MI:0914”(association) | 0.350 |
| GPSM3 | PHF1 | psi-mi:“MI:0914”(association) | 0.350 |
| LMNB2 | SPOP | psi-mi:“MI:0914”(association) | 0.350 |
| ECE2 | KDM1A | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (278): DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Biochemical Activity), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS), DHX40 (Affinity Capture-MS)
ESM2 similar proteins: A0A193KX02, A0A397HK53, A1Y9I9, A4IG53, A5WWC6, B6CZ46, B6CZ56, B6CZ62, B8NR70, L0TAD5, O42898, P37059, P55205, P58781, P86243, Q0IIS3, Q0P464, Q28C60, Q28DI5, Q2KHV5, Q2VQV9, Q32LS6, Q3V1F8, Q4V339, Q5JTY5, Q5RIA9, Q5XI69, Q5XI79, Q66KL0, Q68EZ3, Q6DCK1, Q6GQ37, Q6PE54, Q6Q2C2, Q6TL19, Q7L592, Q7L5L3, Q8IUF1, Q8IX18, Q8NKC1
Diamond homologs: A1Z9L3, A2A4P0, B4GEU5, B4JT42, B4K5R2, B4RC48, D4A2Z8, F4HYJ7, F4IE66, F4IJV4, F4ILR7, F4IM84, F4JMJ3, F4JRJ6, F4K2E9, F4KGU4, O17438, O22243, O22899, O35286, O42643, O42945, O43143, O45244, O46072, O51767, O60114, O60231, O70133, O94536, P0C7L7, P0CE10, P15938, P20095, P24384, P34305, P34498, P36009, P37024, P43329
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
88 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 64 |
| Likely benign | 1 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2901 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 17:59566625:A:AG | acceptor_gain | 1.0000 |
| 17:59566626:G:GG | acceptor_gain | 1.0000 |
| 17:59566626:GAA:G | acceptor_gain | 1.0000 |
| 17:59566626:GAAGA:G | acceptor_gain | 1.0000 |
| 17:59566707:GCT:G | donor_gain | 1.0000 |
| 17:59566750:G:GT | donor_gain | 1.0000 |
| 17:59573965:GCG:G | donor_gain | 1.0000 |
| 17:59575335:TTTA:T | acceptor_loss | 1.0000 |
| 17:59575336:TTAG:T | acceptor_loss | 1.0000 |
| 17:59575337:TA:T | acceptor_loss | 1.0000 |
| 17:59575338:A:AG | acceptor_gain | 1.0000 |
| 17:59575338:AGG:A | acceptor_loss | 1.0000 |
| 17:59575339:G:GG | acceptor_gain | 1.0000 |
| 17:59575339:GGCC:G | acceptor_gain | 1.0000 |
| 17:59575339:GGCCA:G | acceptor_gain | 1.0000 |
| 17:59575467:AACAG:A | donor_loss | 1.0000 |
| 17:59575468:ACAGG:A | donor_loss | 1.0000 |
| 17:59575470:AG:A | donor_loss | 1.0000 |
| 17:59575471:GGT:G | donor_loss | 1.0000 |
| 17:59575472:G:GA | donor_loss | 1.0000 |
| 17:59575473:T:A | donor_loss | 1.0000 |
| 17:59577253:A:AG | acceptor_gain | 1.0000 |
| 17:59577254:T:G | acceptor_gain | 1.0000 |
| 17:59577255:A:AG | acceptor_gain | 1.0000 |
| 17:59577256:T:G | acceptor_gain | 1.0000 |
| 17:59577257:A:AG | acceptor_gain | 1.0000 |
| 17:59577258:T:G | acceptor_gain | 1.0000 |
| 17:59577259:A:AG | acceptor_gain | 1.0000 |
| 17:59577264:A:AG | acceptor_gain | 1.0000 |
| 17:59577265:G:GA | acceptor_gain | 1.0000 |
AlphaMissense
5110 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:59577308:G:C | R339T | 0.999 |
| 17:59577309:A:C | R339S | 0.999 |
| 17:59577309:A:T | R339S | 0.999 |
| 17:59577313:T:C | C341R | 0.999 |
| 17:59574245:T:C | F278L | 0.998 |
| 17:59574247:T:A | F278L | 0.998 |
| 17:59574247:T:G | F278L | 0.998 |
| 17:59577307:A:G | R339G | 0.998 |
| 17:59577315:T:G | C341W | 0.998 |
| 17:59577317:T:A | V342D | 0.998 |
| 17:59577322:T:C | S344P | 0.998 |
| 17:59579704:G:C | A390P | 0.998 |
| 17:59579726:C:A | A397D | 0.998 |
| 17:59574234:A:T | D274V | 0.997 |
| 17:59577308:G:T | R339I | 0.997 |
| 17:59579714:G:C | R393P | 0.997 |
| 17:59579751:C:G | C405W | 0.997 |
| 17:59579756:G:C | R407P | 0.997 |
| 17:59574213:A:G | H267R | 0.996 |
| 17:59574243:T:A | V277D | 0.996 |
| 17:59575373:T:C | L292P | 0.996 |
| 17:59575384:G:C | A296P | 0.996 |
| 17:59577310:A:G | K340E | 0.996 |
| 17:59577312:A:C | K340N | 0.996 |
| 17:59577312:A:T | K340N | 0.996 |
| 17:59577323:C:A | S344Y | 0.996 |
| 17:59577323:C:T | S344F | 0.996 |
| 17:59579480:T:A | V361E | 0.996 |
| 17:59579482:G:C | D362H | 0.996 |
| 17:59579723:G:C | R396P | 0.996 |
dbSNP variants (sampled 300 via entrez): RS1000083997 (17:59568458 T>A), RS1000160867 (17:59596810 A>C), RS1000296399 (17:59597162 G>A), RS1000425024 (17:59573840 C>G,T), RS1000602625 (17:59598547 A>G), RS1000769166 (17:59570442 T>C), RS1000775022 (17:59604761 A>G), RS1000801627 (17:59570182 A>G), RS1000819083 (17:59585869 G>T), RS1000837753 (17:59603208 C>A), RS1000915468 (17:59586109 G>A,T), RS1000935457 (17:59573511 T>G), RS1000955080 (17:59603203 T>A), RS1000987378 (17:59565297 C>T), RS1001007337 (17:59591609 A>G)
Disease associations
OMIM: gene MIM:607570 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL5465330 (SINGLE PROTEIN)
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
34 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, affects cotreatment, increases abundance, increases expression | 2 |
| Air Pollutants | increases abundance, decreases expression, affects expression | 2 |
| Valproic Acid | affects expression, increases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| GSK-J4 | increases expression | 1 |
| TAK-243 | increases sumoylation | 1 |
| dicrotophos | decreases expression | 1 |
| 2,4,5,2’,4’,5’-hexachlorobiphenyl | decreases expression | 1 |
| cobaltous chloride | increases expression | 1 |
| beta-methylcholine | affects expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CGP 52608 | increases reaction, affects binding | 1 |
| K 7174 | decreases expression | 1 |
| bisphenol S | decreases methylation | 1 |
| Arsenic | affects cotreatment, increases abundance, increases expression | 1 |
| Benzo(a)pyrene | decreases methylation | 1 |
| Cadmium | increases expression, increases abundance | 1 |
| Diazinon | increases methylation | 1 |
| Diethylhexyl Phthalate | increases expression | 1 |
| Ivermectin | decreases expression | 1 |
| Lead | affects expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Ozone | increases abundance, affects expression | 1 |
| Quercetin | decreases expression | 1 |
| Ribonucleotides | affects binding | 1 |
| Testosterone | increases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Tretinoin | decreases expression | 1 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 1 |
| Aflatoxin B1 | increases expression | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5391280 | Binding | Inhibition of N-terminal thioredoxin-tagged human recombinant DHX40 transformed in Escherichia coli BL21(DE3)pLysS cells | Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents. — Bioorg Med Chem Lett |
Cellosaurus cell lines
1 cell lines: 1 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_XN29 | HAP1 DHX40 (-) | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.